Tracon Bows Out Of Oncology For Lead Product As TAPPAS Is Stopped For Futility
Executive Summary
Disappointment for the San Diego, CA-based firm as Phase III study of its lead product is deemed futile and it ends clinical research of the product in cancer.
You may also be interested in...
mRNA Vaccines – Trials Line Up Against Coronavirus
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
Novartis Close To EU Approval For Zolgensma At Last
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
mRNA Vaccines – A Novel Weapon Against Coronavirus
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
Need a specific report? 1000+ reports available
Buy Reports